ABSTRACT
Objective To observe and compare the genomic and transcription level of protein phosphatase 1 regulatory subunit 16A (PPP1R16A) gene in human hepatocellular carcinoma (HCC) tissues and adjacent tissues, and to explore the effect of specific sliencing of PPP1R16A on the proliferation of HCC LM3 cells. Methods Quantitative reverse transcription PCR (qRT-PCR) was used to assess genomic and transcription level of PPP1R16A gene. The specific small interfering RNA (siRNA) of PPP1R16A was synthetized in vitro, and was transfected into HCC LM3 cells with liposome. The experiment was divided into the following three groups, namely, PPP1R16A-siRNA (si-16A) transfected group, non-specific siRNA (NC) transfected group and blank control group. The genomic and transcription level of PPP1R16A gene was detected by qRT-PCR. The expression of PPP1R16A protein was detected by Western blotting analysis. CCK-8 and clone formation assay were used to investigate the proliferation ability of transfected cells. Cell cycle was investigated by flow cytometry. Results The genomic level (P<0.001) and transcription level (P<0.001) of PPP1R16A gene in human HCC tissues were significantly increased compared with those in the adjacent liver tissues; and the genomic level was found significantly correlated with transcription level of PPP1R16A gene (P=0.015). The results of CCK-8 and clone formation experiment in vitro showed that the cell proliferation of si-16A group was significantly inhibited compared with NC group and blank control group (P<0.001). Flow cytometry showed that cell cycle was suppressed in si-16A group. Conclusion The genomic and transcription levels of PPP1R16A gene are increased in HCC tissues. The proliferation of HCC LM3 cells is suppressed by inhibiting the PPP1R16A gene transcription, which suggests that PPP1R16A gene functions as an oncogene in HCC.
ABSTRACT
Hepatocellular carcinoma (HCC) is an aggressive malignancy with a high mortality rate. Prognosis can be improved significantly with early diagnosis. However, current imaging technologies and tumor biomarkers for early diagnosis of HCC are unsatisfied. Emerging evidence shows that tumor cells release substantial amounts of RNAs into the circulation that can not be degraded by ribonucleases and are present at sufficient levels for quantitative analyses.Long non-coding RNAs(lncRNAs) play critical roles in the development of HCC. Some lncRNAs have been reported significantly altered in expression with HCC progression, and they may thus serve as potential diagnostic biomarkers for HCC. This review summarized the recent advance in circulating lncRNAs as diagnosis biomarkers for HCC.